Oppenheimer Trims Intellia Therapeutics (NASDAQ:NTLA) Target Price to $130.00

Intellia Therapeutics (NASDAQ:NTLAGet Rating) had its price target dropped by Oppenheimer from $160.00 to $130.00 in a report issued on Monday, The Fly reports. Oppenheimer’s target price indicates a potential upside of 173.28% from the company’s previous close.

NTLA has been the subject of a number of other reports. Credit Suisse Group started coverage on shares of Intellia Therapeutics in a research report on Thursday, April 28th. They set an “outperform” rating and a $100.00 price target for the company. Brookline Capital Acquisition upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 target price on the stock in a research note on Monday, March 7th. Cowen began coverage on Intellia Therapeutics in a research report on Monday, January 31st. They set an “outperform” rating for the company. JMP Securities decreased their price objective on shares of Intellia Therapeutics from $165.00 to $110.00 in a research report on Monday. Finally, William Blair started coverage on shares of Intellia Therapeutics in a research report on Friday, February 18th. They set an “outperform” rating and a $144.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $143.50.

Shares of NASDAQ NTLA opened at $47.57 on Monday. The company has a market cap of $3.60 billion, a P/E ratio of -9.46 and a beta of 2.14. Intellia Therapeutics has a 52 week low of $44.00 and a 52 week high of $202.73. The business has a 50-day simple moving average of $63.41 and a two-hundred day simple moving average of $93.82.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($1.96) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.85). The firm had revenue of $11.30 million during the quarter, compared to the consensus estimate of $8.57 million. Intellia Therapeutics had a negative net margin of 973.48% and a negative return on equity of 41.85%. Intellia Therapeutics’s revenue was up 73.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.69) earnings per share. On average, equities research analysts predict that Intellia Therapeutics will post -4.36 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in Intellia Therapeutics by 85.0% in the third quarter. Wellington Management Group LLP now owns 583,808 shares of the company’s stock valued at $78,317,000 after purchasing an additional 268,167 shares during the last quarter. American Century Companies Inc. raised its holdings in Intellia Therapeutics by 4.0% during the 4th quarter. American Century Companies Inc. now owns 74,563 shares of the company’s stock valued at $8,816,000 after buying an additional 2,864 shares during the last quarter. Bellevue Group AG purchased a new stake in Intellia Therapeutics during the 3rd quarter valued at $2,226,000. FourThought Financial LLC grew its holdings in Intellia Therapeutics by 518.3% in the 3rd quarter. FourThought Financial LLC now owns 371 shares of the company’s stock worth $49,000 after acquiring an additional 311 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Intellia Therapeutics by 6.3% in the third quarter. California Public Employees Retirement System now owns 152,884 shares of the company’s stock valued at $20,509,000 after acquiring an additional 9,125 shares during the period. Institutional investors and hedge funds own 85.89% of the company’s stock.

Intellia Therapeutics Company Profile (Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Further Reading

The Fly logo

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.